Kura Oncology (KURA) Q3 2026 earnings review
Kura's leukemia pill sales jump, and new funding extends cash
Kura Oncology, a maker of targeted cancer pills, grew sales of its leukemia drug faster than expected as early patients came back for refills. KOMZIFTI sales rose 53% from last quarter to $13.9 million, passing non-cash partner revenue for the first time as total prescriptions jumped 65%. Chief executive Troy Wilson said the drug kept a majority of new patient starts in its class, though the company cut its 2026 outlook for non-cash accounting revenue from partner Kyowa Kirin to $40–45 million.
| KOMZIFTI net product sales | $13.9M +53% from last quarter |
|---|---|
| Total prescriptions | >420 +65% from last quarter (~150 new starts, +30%) |
| Cash and short-term investments | $492.1M plus up to $300M Oberland facility ($55M drawn) |
| 2026 collaboration revenue outlook | Cut $7.5M now $40–45M; 2027 held at $90–110M |
⚖️ Verdict: 🟢 Bullish
The story got better because Kura addressed its two biggest near-term hurdles: how to fund trials past 2027 and how to get its second drug approved without a massive study. A new financing deal for up to $300 million removes the pressure for a near-term stock sale, and regulators agreed that a 40-patient trial could support approval for darlifarnib in salivary gland cancer. One caution: the loan deal gives lenders a royalty on U.S. KOMZIFTI sales, which Kura already splits evenly with Kyowa Kirin.
The question now is how much money KOMZIFTI can make in relapsed leukemia while investors wait for 2028 trials in newly diagnosed patients. Either combinations keep patients on the pill for many months and build a large recurring base, or short treatment durations and shared royalties cap the cash flow. December conference data on combination trials and future disclosure of treatment duration will tell.
🐂 Bull Case
Repeat Prescriptions Lifted KOMZIFTI Sales 53%
KOMZIFTI, Kura's daily pill for patients whose acute myeloid leukemia returned after treatment and carries an NPM1 gene mutation, is in its third full quarter on the market. Chief executive Troy Wilson said the drug "delivered strong commercial performance this quarter" and kept a majority of new patients starting this class of medicine.
- Net product sales: $13.9 million, up 53% from $9.1 million last quarter
- New patient starts: about 150, up 30% from about 115 last quarter
- Total prescriptions, including refills: more than 420, up 65% from 250 last quarter
- Revenue per prescription: about $33,100 by our math, compared with $36,500 last quarter
Total prescriptions grew more than twice as fast as new patient starts because earlier patients stayed on the drug and refilled their monthly prescriptions. Product sales now make up 61% of total revenue, up from 44% last quarter, so cash sales from patients now outweigh accounting revenue from Kura's partner.
What to watch: the average months a patient stays on KOMZIFTI, which management still has not disclosed. If patients stay on the drug longer via combination treatments, refill prescriptions will keep growing faster than new starts.
FDA Agreement Opens a Fast Path for Darlifarnib
Darlifarnib is Kura's second experimental cancer drug, designed to block cell-signaling proteins in solid tumors. Until now, the San Diego biotech tested it mainly alongside other drugs in early kidney and pancreatic cancer studies.
This quarter Kura reached an agreement with the U.S. Food and Drug Administration on a trial design that could win approval for darlifarnib on its own. The company will run a single-group study of about 40 patients with salivary gland cancer carrying an HRAS gene mutation, starting in the first half of 2027. Wilson said the agreement gives the drug maker "providing a potential path to our second product approval as we continue to pursue broader opportunities with combinations in solid tumors".
What to watch: enrollment completion in the separate kidney cancer combination study in the first half of 2027, followed by initial results in the second half. Strong kidney cancer results would show darlifarnib works in a large cancer market as well as a small niche.
Leukemia Combination Trials Reach the December Conference
To expand ziftomenib beyond patients who have exhausted other options, Kura is testing the pill alongside standard chemotherapy and targeted drugs in newly diagnosed leukemia. The biotech promised four clinical updates for the second half of 2026.
All four arrived among eight studies accepted for the American Society of Hematology meeting in December 2026. Two oral talks will show "encouraging preliminary results for ziftomenib plus quizartinib and 7+3 intensive chemotherapy" in newly diagnosed patients and a combination with gilteritinib in relapsed patients. Posters will update long-term survival in older patients and test whether new genetic groups respond.
What to watch: remission and safety rates in the two December oral presentations on FLT3-mutated leukemia. Clean safety alongside high remission rates would support doctors who combine the drug with other therapies.
🐻 Bear Case
Oberland Deal Adds $300M of Capacity at a Royalty Cost
Before this quarter, Kura's cash covered its standalone spending only into late 2027, while its pivotal frontline leukemia trial does not read out until 2028. Management relied on $180 million in expected milestone payments from partner Kyowa Kirin to bridge that gap.
To add a buffer, the drug maker signed a financing deal with Oberland Capital for up to $275 million in seven-year loans and $25 million in stock. Kura took $50 million in debt and $5 million in equity at closing. The loans carry interest of 6.95% to 8.95% plus a "single-digit royalty tied to U.S. KOMZIFTI net sales, capped at 20% of the aggregate principal amount of term loans advanced under the agreement".
The deal reduces the chance of a large stock sale before 2028, because half the interest is added to the loan balance for three years. However, Kura already splits U.S. KOMZIFTI profits evenly with Kyowa Kirin, so the new royalty further trims what Kura keeps from its own drug.
What to watch: whether Kura draws more Oberland loan tranches or collects the $180 million from Kyowa Kirin first. Drawing more loans would increase the total royalty cap on U.S. KOMZIFTI sales.
Cut in 2026 Partner Revenue Steepens the 2027 Step-Up
Alongside drug sales, Kura books collaboration revenue from the upfront and milestone cash Kyowa Kirin already paid. The company calls this line "non-cash accounting recognition as Kura fulfills performance obligations under its agreement with Kyowa Kirin and does not reflect the timing of cash receipts".
That accounting revenue fell for a fourth straight quarter to $8.9 million, down 24% from last quarter and below the $10.4 million to $15.4 million pace implied by the old full-year plan by our math. Kura cut its 2026 collaboration outlook from $45–55 million to $40–45 million, yet kept its 2027 and 2028 targets at $90–110 million a year. Hitting 2027 now requires quarterly recognition to nearly triple from today's level.
What to watch: first-quarter 2027 collaboration revenue and the deferred revenue schedule in the annual filing. If quarterly recognition stays near $9 million, the company will have to cut its 2027 outlook as well.
Risks this quarter didn't answer
Four standing risks around KOMZIFTI's commercial ceiling and clinical timeline received no new figures in the third-quarter earnings release.
- Treatment duration: management still has not shared how many months an average patient stays on KOMZIFTI before stopping.
- Market share math: Kura again claimed a majority of new patient starts, while rival Syndax has claimed 60% to 67% of the same patient group; no third-party prescription split was published.
- Off-label combination use and safety: the share of doctors prescribing KOMZIFTI alongside unapproved partners (previously about 40%) was not updated, and the drug carries a boxed warning for differentiation syndrome, an immune reaction that affected 26% of trial patients.
- Frontline Phase 3 readout: initial results from the KOMET-017 trials in newly diagnosed leukemia remain two years away in 2028.
👓 Other Themes
Diabetes Drug Spun Out Into a $50M Partnered Venture
Kura had planned to fund early diabetes studies for its next-generation menin drugs with outside money. This quarter it formed a separate company, Caspian Therapeutics, which raised $50 million from investors including BVF Partners and Eli Lilly. That moves diabetes research costs off Kura's budget. Separately, Kura hired former Eli Lilly and Soleno executive Jennifer Fulk as finance chief in September.
💲 Other KPIs
Cash and short-term investments dipped by $26.9 million from last quarter, compared with a $61.8 million drop in the second quarter. The third-quarter balance benefited from the initial $55 million gross proceeds from the Oberland Capital financing.
The quarterly net loss widened slightly from $68.3 million in the second quarter, bit narrowed by 5.3% from $74.1 million a year ago. Research and development spending rose to $66.9 million as Phase 3 trials enrolled patients, while selling and administrative costs edged down from last quarter to $30.2 million.
Stockholders' equity — total assets minus liabilities — fell from $48.4 million in June and $174.1 million at the end of 2025. Because upfront partner cash sits on the balance sheet as a $400 million long-term liability until recognized, ongoing quarterly losses have nearly wiped out book equity.
🔮 Guidance
Cut. Management lowered the middle of the 2026 non-cash partner revenue plan by $7.5 million after holding it at $45–55 million for three quarters. By our math, with $33.2 million booked in the first nine months, the new plan leaves about $9.3 million for the fourth quarter, almost unchanged from the third quarter's $8.9 million.
Unchanged. The biotech kept its non-cash partner revenue forecast at $90–110 million for both 2027 and 2028 for a fourth straight quarter. Because the 2026 outlook came down, reaching the middle of the 2027 range now requires annual recognition to jump by 135% by our math, or about $25 million a quarter.
❓ Key Questions
How long do patients stay on KOMZIFTI?
Total prescriptions grew 65% while new patient starts rose 30%, showing strong refills. Yet management has not disclosed average treatment duration across three launch quarters, nor split refills between single-drug and combination use.
Why will partner revenue double in 2027 after a 2026 cut?
Quarterly collaboration revenue slid from $20.8 million a year ago to $8.9 million, forcing a 2026 forecast cut. Management still projects $90–110 million in 2027 without explaining what accounting trigger causes that jump.
What triggers the $180 million in Kyowa Kirin milestones?
Kura includes $180 million of future Kyowa Kirin payments in its 2028 cash runway, and now added Oberland debt. Investors still do not know which clinical events unlock the Kyowa Kirin cash or when they arrive.
What is Kura's ownership stake in Caspian Therapeutics?
Caspian raised $50 million from outside investors and Kura to develop menin inhibitors for diabetes. The release does not state how much cash Kura contributed or what percentage of Caspian it still owns.